Avanos Medical Statistics
Total Valuation
Avanos Medical has a market cap or net worth of $1.15 billion. The enterprise value is $1.19 billion.
Important Dates
The next estimated earnings date is Monday, May 4, 2026, before market open.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 46.67 million shares outstanding. The number of shares has increased by 0.65% in one year.
| Current Share Class | 46.67M |
| Shares Outstanding | 46.67M |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.51% |
| Owned by Institutions (%) | 90.83% |
| Float | 42.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 24.63 |
| PS Ratio | 1.64 |
| Forward PS | 1.59 |
| PB Ratio | 1.47 |
| P/TBV Ratio | 4.33 |
| P/FCF Ratio | 26.68 |
| P/OCF Ratio | 15.39 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 21.86, with an EV/FCF ratio of 27.59.
| EV / Earnings | n/a |
| EV / Sales | 1.70 |
| EV / EBITDA | 21.86 |
| EV / EBIT | 76.72 |
| EV / FCF | 27.59 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.15 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | 3.00 |
| Interest Coverage | 1.99 |
Financial Efficiency
Return on equity (ROE) is -9.07% and return on invested capital (ROIC) is 1.87%.
| Return on Equity (ROE) | -9.07% |
| Return on Assets (ROA) | 0.87% |
| Return on Invested Capital (ROIC) | 1.87% |
| Return on Capital Employed (ROCE) | 1.71% |
| Weighted Average Cost of Capital (WACC) | 9.50% |
| Revenue Per Employee | $306,603 |
| Profits Per Employee | -$31,876 |
| Employee Count | 2,287 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.42 |
Taxes
In the past 12 months, Avanos Medical has paid $6.70 million in taxes.
| Income Tax | 6.70M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +99.43% in the last 52 weeks. The beta is 1.05, so Avanos Medical's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +99.43% |
| 50-Day Moving Average | 16.30 |
| 200-Day Moving Average | 12.95 |
| Relative Strength Index (RSI) | 90.34 |
| Average Volume (20 Days) | 2,327,200 |
Short Selling Information
The latest short interest is 2.00 million, so 4.29% of the outstanding shares have been sold short.
| Short Interest | 2.00M |
| Short Previous Month | 2.33M |
| Short % of Shares Out | 4.29% |
| Short % of Float | 4.75% |
| Short Ratio (days to cover) | 1.17 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $701.20 million and -$72.90 million in losses. Loss per share was -$1.57.
| Revenue | 701.20M |
| Gross Profit | 353.90M |
| Operating Income | 15.50M |
| Pretax Income | -66.20M |
| Net Income | -72.90M |
| EBITDA | 54.40M |
| EBIT | 15.50M |
| Loss Per Share | -$1.57 |
Full Income StatementBalance Sheet
The company has $89.80 million in cash and $129.10 million in debt, giving a net cash position of -$39.30 million or -$0.84 per share.
| Cash & Cash Equivalents | 89.80M |
| Total Debt | 129.10M |
| Net Cash | -39.30M |
| Net Cash Per Share | -$0.84 |
| Equity (Book Value) | 778.20M |
| Book Value Per Share | 16.75 |
| Working Capital | 190.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $74.70 million and capital expenditures -$31.60 million, giving a free cash flow of $43.10 million.
| Operating Cash Flow | 74.70M |
| Capital Expenditures | -31.60M |
| Depreciation & Amortization | 38.90M |
| Net Borrowing | -34.40M |
| Free Cash Flow | 43.10M |
| FCF Per Share | $0.92 |
Full Cash Flow StatementMargins
Gross margin is 50.47%, with operating and profit margins of 2.21% and -10.40%.
| Gross Margin | 50.47% |
| Operating Margin | 2.21% |
| Pretax Margin | -9.44% |
| Profit Margin | -10.40% |
| EBITDA Margin | 7.76% |
| EBIT Margin | 2.21% |
| FCF Margin | 6.15% |